This company has made its pitch for 3 years to get the $10-15M for the phase 2 trial from companies and individuals in the business of funding biotech research. Sorry, but those "in the business" of providing that funding and declining to fork over the $15M outrank OTC "valuations" in the billions and 100 millions all day long.